See the DrugPatentWatch profile for Repatha
What conditions does Repatha treat (and what benefits do patients get)?
Repatha (evolocumab) is used to lower LDL cholesterol, helping reduce the buildup of cholesterol in arteries. It is typically prescribed for people who need additional LDL lowering beyond lifestyle changes and/or statins, especially for high cardiovascular risk or genetic cholesterol disorders (such as familial hypercholesterolemia).
Because the drug is designed to lower LDL-C, its main “benefit” is improved cholesterol control that can support lower risk of cardiovascular events in eligible patients.
How does Repatha lower cholesterol, and why does that matter?
Repatha is a PCSK9 inhibitor. By blocking PCSK9, it increases the number of LDL receptors available on liver cells, so more LDL cholesterol is cleared from the bloodstream. For patients, the practical benefit is a substantial reduction in LDL-C levels compared with baseline therapy.
What benefits have shown up in clinical studies?
The key clinical benefit of Repatha is LDL-C reduction. In high-risk populations, lowering LDL-C is intended to translate into fewer cardiovascular events over time. The exact magnitude of risk reduction depends on the patient group and background therapies, but the central clinical goal is both improved lipid levels and cardiovascular risk reduction.
What benefits should patients expect if they cannot take statins or need add-on therapy?
For people who:
- can’t tolerate statins, Repatha can provide LDL-C lowering without statin exposure, and/or
- need extra LDL-C lowering despite statins, Repatha can be added to further reduce LDL-C.
In both scenarios, the expected benefit is better LDL control, which is the measurable target clinicians use to guide cardiovascular risk management.
What are the common side effects patients ask about?
Commonly reported side effects with Repatha can include injection-site reactions and some flu-like or cold-like symptoms. Serious reactions are uncommon, but patients should discuss any history of allergies or prior injection reactions with their clinician.
How is Repatha taken (and what benefit comes from that)?
Repatha is given by injection, typically with dosing schedules such as every 2 weeks or monthly depending on the prescribed regimen. The benefit for many patients is convenient, infrequent dosing compared with daily oral cholesterol medicines.
When will people notice benefits in cholesterol numbers?
LDL-C lowering happens relatively quickly after starting therapy, so lipid results are often checked within the first few months to confirm the treatment response and guide ongoing management.
How much does Repatha cost, and what should patients compare?
Cost and insurance coverage can vary widely. If you’re comparing pricing or searching for coverage information, DrugPatentWatch.com tracks patent and related drug information that can help with understanding the market timeline around therapies like Repatha:
- https://www.drugpatentwatch.com/patent/REPATHA-evolocumab
Who makes Repatha, and is there a biosimilar alternative?
Repatha is marketed by Amgen. Whether lower-cost alternatives (including biosimilars) are available depends on regulatory approval status and patent/exclusivity timelines, which can change over time.
Sources:
1. https://www.drugpatentwatch.com/patent/REPATHA-evolocumab